84. Sarcoidosis Clinical trials / Disease details


Clinical trials : 149 Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03705884
(ClinicalTrials.gov)
January 1, 20188/8/2018PET/MR Imaging In Patients With Cardiac SarcoidosisMolecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac SarcoidosisCardiac SarcoidosisOther: 18F-FDG;Drug: PrednisoloneUniversity of EdinburghNULLUnknown status40 YearsN/AAll40N/AUnited Kingdom
2NCT03048097
(ClinicalTrials.gov)
February 1, 20172/2/2017Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac SarcoidosisSarcoidosisDrug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion ImagingYale UniversityNULLCompleted18 YearsN/AAll15Early Phase 1United States
3JPRN-jRCTs041180111
16/12/201619/03/2019Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study Cardiac sarcoidosis
Cardiac sarcoidosis
After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 monthsMurohara ToyoakiNULLComplete>= 20age oldNot applicableBoth85Phase 3Japan
4JPRN-UMIN000022996
2016/10/0804/07/2016Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis Myocardial sarcoidosismediacl therapy with methotrexate
medical therapy with steroid
The Department of Cardiology, Nagoya University Graduate School of MedicineNULLRecruiting20years-old90years-oldMale and Female50Not selectedJapan
5EUCTR2015-001815-11-FI
(EUCTR)
19/04/201629/12/2015PET imaging of pulmonary sarcoidosisImaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy.
MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-fluorodeoxyglucose
Product Code: FDG
INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE
Product Name: C11-methionine
INN or Proposed INN: L-methionine
Other descriptive name: L-METHIONINE ([11C]METHYL)
Product Name: 68Ga-DOTANOC
INN or Proposed INN: DOTANOC
Other descriptive name: DOTANOC
Turku PET CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Finland
6JPRN-UMIN000004267
2010/10/0101/10/2010PET/CT finding of cardiac sarcoidosisPET/CT finding of cardiac sarcoidosis - PET/CT finding of cardiac sarcoidosis sarcoidosisGive heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis.Tokushima University HospitalNULLPendingNot applicableNot applicableMale and Female30Not selectedJapan
7JPRN-UMIN000006533
2010/04/0130/10/2011Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effectsDetecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects - Detecting sympathetic denervation and regional myocardial inflammation in patients with cardiac involvement sarcoidosis (CANVAS study) sarcoidosisAll patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations.
Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment.
Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later.
Cardiac sarcoidosis with steroid treatment.

Cardiac sarcoidosis without steroid treatment.
arcoidosis without cardiac involvement who will have steroid treatement.
Sarcoidosis without cardiac involvement who will not have steroid treatement.
Normal control.
Hokkaido University Graduate School of Medicine,NULLRecruitingNot applicableNot applicableMale and Female50Not applicableJapan